Airway Surface Liquid and Impaired Antiviral Defense in Cystic Fibrosis
- PMID: 31348689
- PMCID: PMC6938140
- DOI: 10.1165/rcmb.2019-0239ED
Airway Surface Liquid and Impaired Antiviral Defense in Cystic Fibrosis
Comment on
-
Airway Surface Liquid Has Innate Antiviral Activity That Is Reduced in Cystic Fibrosis.Am J Respir Cell Mol Biol. 2020 Jan;62(1):104-111. doi: 10.1165/rcmb.2018-0304OC. Am J Respir Cell Mol Biol. 2020. PMID: 31242392 Free PMC article.
References
-
- Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653–1658. - PubMed
-
- Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999;103:619–626. - PubMed
-
- Ling KM, Garratt LW, Lassmann T, Stick SM, Kicic A WAERP; AusREC; Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Elucidating the interaction of CF airway epithelial cells and rhinovirus: using the host-pathogen relationship to identify future therapeutic strategies. Front Pharmacol. 2018;9:1270. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
